SCHEMBL144162

SCHEMBL144162

CCOc1ccc2nc(Nc3cc(C(F)(F)c4ccc(F)cc4)nc(N[C@H]4CC[C@H](O)CC4)n3)sc2c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 16/20 0.84
ITK Q08881 16/20 0.84
AURKB Q96GD4 15/20 0.84
EGFR P00533 1/20 0.49
INSR P06213 1/20 0.49
SRC P12931 1/20 0.49
TEC P42680 1/20 0.49
TXK P42681 1/20 0.49
BMX P51813 1/20 0.49
BTK Q06187 1/20 0.49
LRRK2 Q5S007 1/20 0.49
CAMKK2 Q96RR4 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
PKM P14618 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144163 1.00 LCK (0.84) LCKITKAURKBEGFRINSR
SCHEMBL143616 0.92 LCK (1.00) LCKITKAURKBEGFRINSR
SCHEMBL143617 0.92 LCK (1.00) LCKITKAURKBEGFRINSR
SCHEMBL139892 0.87 ITK (0.81) LCKITKAURKBEGFRINSR
SCHEMBL139891 0.87 ITK (0.81) LCKITKAURKBEGFRINSR
SCHEMBL139966 0.87 ITK (0.81) LCKITKAURKBEGFRINSR
SCHEMBL139967 0.87 ITK (0.81) LCKITKAURKBEGFRINSR
SCHEMBL140482 0.86 ITK (0.78) LCKITKAURKBEGFRINSR
SCHEMBL140481 0.86 ITK (0.78) LCKITKAURKBEGFRINSR
SCHEMBL137558 0.85 ITK (0.77) LCKITKAURKBEGFRINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.